Is first eye cataract surgery cost effective?

Article

First eye cataract surgery is probably more cost-effective over a patient's remaining lifetime than if they have no surgery at all.

First eye cataract surgery is probably more cost-effective over a patient's remaining lifetime than if they have no surgery at all, according to a study published in the December issue of the British Journal of Ophthalmology.

Tracey Sach and colleagues from the University of East Anglia, UK evaluated the cost-effectiveness of first eye cataract surgery compared with no surgery from a health service and personal social services perspective. A sample of 306 women aged 70 years or older with bilateral cataracts were randomized to cataract surgery (expedited) or control (routine 12-month wait for surgery).

The operated group cost a mean £2,004 (approx. €2,800) more than the control group over one year. However, they experienced an average 0.456 fewer falls, an incremental cost per fall prevented of £4,390 (approx. €6,150). The mean gain in quality of life years (QALYs) per patient was 0.056. The incremental cost-utility ratio was £35,704 (approx. €50,000), above the currently accepted UK threshold level of willingness to pay per QALY of £30,000 (approx. €42,000). However, in an analysis modelling costs and benefits over a patients' expected lifetime, the incremental cost per QALY was £13,172 (approx. €18,500) under conservative assumptions.

According to the researchers, although first eye cataract surgery was not cost-effective over the trial period, it is probably more cost-effective over a patients' remaining lifetime, than if they had no surgery at all.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.